Monday, October 5, 2015
EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.
Exelixis has announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase III trial. William Berg, M.D., has joined the company as senior vice president of medical affairs, Jonathan Berndt as vice president of sales, and Gregg Bernier as vice president of marketing.
ERT, a global provider of patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, has experienced record growth in its ERT Insights Cloud solution—a suite of data analytics visualization and workflow applications for use in pharmaceutical clinical development.
Pharmaceutical Product Development (PPD) has earned recognition for excellence in multimedia and digital communications that promote the people and technology vital to advancing the development of life-changing medicines. PPD earned five honors in the annual Telly Awards and three in the Digital Health Awards.
Bellerophon Therapeutics, a clinical stage biotherapeutics company, has announced changes to its leadership team to align with the company’s focus of progressing its nitric oxide therapy program for patients suffering from pulmonary hypertension (PH), using Bellerophon’s proprietary INOpulse delivery system.
Biogen, based in Cambridge, Mass., has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World) for the second year in a row, after becoming the first U.S.-based biotech company to make the list in 2013. The company also was named to the Dow Jones Sustainability Index North America for the sixth consecutive year, one of only three biotech companies included.